BR9707807A - Uso de uma composição farmacêutica composição farmacêutica processo de tratar doenças ou distúrbios associados com a regulação do apetite prejudicado e uso de um peptideo - Google Patents

Uso de uma composição farmacêutica composição farmacêutica processo de tratar doenças ou distúrbios associados com a regulação do apetite prejudicado e uso de um peptideo

Info

Publication number
BR9707807A
BR9707807A BR9707807A BR9707807A BR9707807A BR 9707807 A BR9707807 A BR 9707807A BR 9707807 A BR9707807 A BR 9707807A BR 9707807 A BR9707807 A BR 9707807A BR 9707807 A BR9707807 A BR 9707807A
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
peptide
regulation
disorders associated
treating diseases
Prior art date
Application number
BR9707807A
Other languages
English (en)
Inventor
Lars Thim
Wuff Birgitte Schiellerup
Martin Edward Judge
Ole Dragabaek Madsen
Jens Juul Horst
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26063575&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9707807(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of BR9707807A publication Critical patent/BR9707807A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Endocrinology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
BR9707807A 1996-03-01 1997-02-27 Uso de uma composição farmacêutica composição farmacêutica processo de tratar doenças ou distúrbios associados com a regulação do apetite prejudicado e uso de um peptideo BR9707807A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DK23096 1996-03-01
DK23196 1996-03-01
PCT/DK1997/000086 WO1997031943A1 (en) 1996-03-01 1997-02-27 Use of a pharmaceutical composition comprising an appetite-suppressing peptide

Publications (1)

Publication Number Publication Date
BR9707807A true BR9707807A (pt) 1999-07-27

Family

ID=26063575

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9707807A BR9707807A (pt) 1996-03-01 1997-02-27 Uso de uma composição farmacêutica composição farmacêutica processo de tratar doenças ou distúrbios associados com a regulação do apetite prejudicado e uso de um peptideo

Country Status (22)

Country Link
EP (4) EP1231218B1 (pt)
JP (1) JP4064460B2 (pt)
KR (1) KR100611130B1 (pt)
CN (1) CN1112367C (pt)
AT (3) ATE395359T1 (pt)
AU (1) AU710818B2 (pt)
BR (1) BR9707807A (pt)
CA (1) CA2246733C (pt)
CY (2) CY2619B2 (pt)
CZ (1) CZ297338B6 (pt)
DE (3) DE69717092T2 (pt)
DK (2) DK0891378T3 (pt)
ES (3) ES2364705T3 (pt)
FR (1) FR13C0009I2 (pt)
HU (1) HU229234B1 (pt)
IL (1) IL125805A0 (pt)
NO (2) NO323043B1 (pt)
PL (1) PL187095B1 (pt)
PT (1) PT1975177E (pt)
RU (1) RU2197261C2 (pt)
UA (1) UA70283C2 (pt)
WO (1) WO1997031943A1 (pt)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5834428A (en) 1995-04-14 1998-11-10 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
US6184201B1 (en) 1995-04-14 2001-02-06 Nps Allelix Corp. Intestinotrophic glucagon-like peptide-2 analogs
US5990077A (en) * 1995-04-14 1999-11-23 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
US6852690B1 (en) 1995-08-22 2005-02-08 Amylin Pharmaceuticals, Inc. Method and composition for enhanced parenteral nutrition
AU710818B2 (en) * 1996-03-01 1999-09-30 Novo Nordisk A/S Use of a pharmaceutical composition comprising an appetite-suppressing peptide
AU733857B2 (en) 1996-04-12 2001-05-31 1149336 Ontario Inc. Glucagon-like peptide-2 analogs
US6458924B2 (en) 1996-08-30 2002-10-01 Novo Nordisk A/S Derivatives of GLP-1 analogs
US7235627B2 (en) 1996-08-30 2007-06-26 Novo Nordisk A/S Derivatives of GLP-1 analogs
UA65549C2 (uk) 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
AU4863797A (en) * 1996-11-12 1998-06-03 Novo Nordisk A/S Use of glp-1 peptides
US6051557A (en) * 1997-05-16 2000-04-18 1149336 Ontario Inc. Methods of enhancing functioning of the upper gastrointestinal tract
JP2001516765A (ja) * 1997-09-12 2001-10-02 ヴォルフ ゲオルグ フォースマン 真性糖尿病及び肥満の治療のための組成物
JP2001525371A (ja) 1997-12-05 2001-12-11 イーライ・リリー・アンド・カンパニー Ｇｌｐ−１製剤
WO1999043361A1 (en) * 1998-02-27 1999-09-02 Novo Nordisk A/S Glp-2 derivatives with helix-content exceeding 25 %, forming partially structured micellar-like aggregates
EP1062240B1 (en) * 1998-02-27 2010-04-28 Novo Nordisk A/S N-terminally modified glp-1 derivatives
EP1056774A1 (en) * 1998-02-27 2000-12-06 Novo Nordisk A/S N-terminally truncated glp-1 derivatives
WO1999047161A1 (en) * 1998-03-19 1999-09-23 Bionebraska, Inc. Human appetite control by glucagon-like peptide receptor binding compounds
US6998387B1 (en) 1998-03-19 2006-02-14 Amylin Pharmaceuticals, Inc. Human appetite control by glucagon-like peptide receptor binding compounds
GB2396815B (en) 1999-10-27 2004-09-08 Phytopharm Plc A composition comprising a pregnenone derivative and an NSAID
GB2363985B (en) 2000-06-30 2004-09-29 Phytopharm Plc Extracts,compounds & pharmaceutical compositions having anti-diabetic activity and their use
US7186683B2 (en) 2000-09-18 2007-03-06 Sanos Bioscience A/S Use of GLP for the treatment, prevention, diagnosis, and prognosis of bone-related and nutrition-related disorders
WO2002022151A2 (en) 2000-09-18 2002-03-21 Osteometer Bio Tech A/S Use of glp-1 and flp-2 peptides for treatment of bone disorders
US7371721B2 (en) 2000-09-18 2008-05-13 Sanos Bioscience A/S Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes
EP2062593A3 (en) 2000-12-01 2011-08-17 Takeda Pharmaceutical Company Limited Method for producing preparation containing bioactive peptide
GB0121709D0 (en) * 2001-09-07 2001-10-31 Imp College Innovations Ltd Food inhibition agent
WO2003059934A2 (en) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin fusion proteins
EP2261250B1 (en) 2001-12-21 2015-07-01 Human Genome Sciences, Inc. GCSF-Albumin fusion proteins
WO2004035624A2 (en) 2002-10-14 2004-04-29 Novo Nordisk A/S Glucagon - like peptide - 2 variants
EP1592471B1 (en) 2003-02-04 2011-03-23 Novo Nordisk A/S Injection device with rotatable dose setting mechanism
JP4865565B2 (ja) 2003-12-09 2012-02-01 ノヴォ ノルディスク アー／エス Ｇｌｐ−１アゴニストを用いた食物選択の制御
ATE550041T1 (de) 2004-01-21 2012-04-15 Novo Nordisk Healthcare Ag Transglutaminase-vermittelte konjugation von peptiden
HUE027902T2 (en) 2004-02-09 2016-11-28 Human Genome Sciences Inc Corp Service Company Albumin fusion proteins
EP2409707B8 (en) 2004-04-15 2015-05-06 Alkermes Pharma Ireland Limited Polymer-based sustained release device
US7456254B2 (en) 2004-04-15 2008-11-25 Alkermes, Inc. Polymer-based sustained release device
EP2316446A1 (en) 2004-06-11 2011-05-04 Novo Nordisk A/S Counteracting drug-induced obesity using GLP-1 agonists
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
BRPI0610091B1 (pt) 2005-05-04 2021-08-03 Zealand Pharma A/S Análogo de peptídeo 2 tipo glucagon (glp-2), composição farmacêutica, uso de um análogo de glp-2, e, kit terapêutico
ES2336575T3 (es) 2005-09-22 2010-04-14 Biocompatibles Uk Limited Polipeptidos de fusion glp-1 (peptido-1 similar al glucagon) con resistencia aumentada a la peptidasa.
DE602006009631D1 (de) 2006-05-10 2009-11-19 Biocompatibles Uk Ltd GLP-1 Peptide enthaltende kugelförmige Mikrokapseln, deren Produktion und deren Verwendung
AU2007284759B2 (en) 2006-08-09 2010-10-28 Intarcia Therapeutics, Inc. Osmotic delivery systems and piston assemblies
CN101573376B (zh) 2006-11-08 2013-11-06 西兰制药公司 选择性胰高血糖素样肽-2（glp-2）类似物
AU2008244523B2 (en) 2007-04-23 2012-02-16 Intarcia Therapeutics, Inc. Suspension formulations of insulinotropic peptides and uses thereof
AU2008286706B2 (en) * 2007-08-16 2014-03-06 Garvan Institute Of Medical Research Agents and methods for modulating macrophage inhibitory cytokine (MIC-1) activity
EP2240155B1 (en) 2008-02-13 2012-06-06 Intarcia Therapeutics, Inc Devices, formulations, and methods for delivery of multiple beneficial agents
ES2360782B1 (es) * 2009-07-28 2012-03-12 Grifols, S.A. Medios para cultivo de células de mamíferos que comprenden sobrenadante de etapas del fraccionamiento de Cohn y uso de los mismos.
RU2547990C2 (ru) 2009-09-28 2015-04-10 Интарсия Терапьютикс, Инк. Быстрое достижение и/или прекращение существенной стабильной доставки лекарственного средства
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
TR201802689T4 (tr) 2012-05-03 2018-03-21 Zealand Pharma As Glukagon benzeri peptit-2 (glp-2) analogları.
US20150157619A1 (en) 2012-07-10 2015-06-11 Takeda Pharmaceutical Company Limited Pharmaceutical preparation for injection
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
KR101576126B1 (ko) 2014-12-29 2015-12-11 부경대학교 산학협력단 αＡＬ１４ 펩타이드를 유효성분으로 함유하는 신규 비만 예방 및 치료용 약학적 조성물
KR101669140B1 (ko) * 2015-04-28 2016-10-26 (주)케어젠 항비만 및 항당뇨 효능을 갖는 펩타이드 및 이의 용도
EP3302354B1 (en) 2015-06-03 2023-10-04 i2o Therapeutics, Inc. Implant placement systems
US10188135B2 (en) * 2015-11-04 2019-01-29 Stokley-Van Camp, Inc. Method for inducing satiety
KR101887576B1 (ko) * 2016-04-15 2018-08-13 (주)케어젠 항비만 및 항당뇨 효능을 갖는 펩타이드 및 이의 용도
RU2760007C2 (ru) 2016-05-16 2021-11-22 Интарсия Терапьютикс, Инк. Полипептиды, селективные к рецепторам глюкагона, и способы их применения
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
JP6563614B1 (ja) 2016-12-09 2019-08-21 ジーランド・ファーマ・ア／エス アシル化ｇｌｐ−１／ｇｌｐ−２二重アゴニスト
WO2018129058A1 (en) 2017-01-03 2018-07-12 Intarcia Therapeutics, Inc. Methods comprising continuous administration of a glp-1 receptor agonist and co-adminstration of a drug
EP3966224A4 (en) * 2019-05-06 2023-08-23 The University of Sydney PROTEIN FRACTIONATION METHODS

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4203570A (en) 1978-08-23 1980-05-20 The Western States Machine Company Power-operated loading gate for centrifugal machines incorporating an auxiliary drive device
US4546082A (en) 1982-06-17 1985-10-08 Regents Of The Univ. Of California E. coli/Saccharomyces cerevisiae plasmid cloning vector containing the alpha-factor gene for secretion and processing of hybrid proteins
US4599311A (en) 1982-08-13 1986-07-08 Kawasaki Glenn H Glycolytic promotersfor regulated protein expression: protease inhibitor
EP0116201B1 (en) 1983-01-12 1992-04-22 Chiron Corporation Secretory expression in eukaryotes
JPS60501140A (ja) 1983-04-22 1985-07-25 アムジエン 酵母による外因性ポリペプチドの分泌
NZ207926A (en) 1983-04-25 1988-04-29 Genentech Inc Use of yeast #a#-factor to assist in expression of proteins heterologus to yeast
US4745051A (en) 1983-05-27 1988-05-17 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
US4870008A (en) 1983-08-12 1989-09-26 Chiron Corporation Secretory expression in eukaryotes
US4879236A (en) 1984-05-16 1989-11-07 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
US4931373A (en) 1984-05-25 1990-06-05 Zymogenetics, Inc. Stable DNA constructs for expression of α-1 antitrypsin
DK58285D0 (da) 1984-05-30 1985-02-08 Novo Industri As Peptider samt fremstilling og anvendelse deraf
US4766073A (en) 1985-02-25 1988-08-23 Zymogenetics Inc. Expression of biologically active PDGF analogs in eucaryotic cells
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4882279A (en) 1985-10-25 1989-11-21 Phillips Petroleum Company Site selective genomic modification of yeast of the genus pichia
WO1987002670A1 (en) 1985-10-25 1987-05-07 Mackay Vivian L Method of using bar1 for secreting foreign proteins
AU607690B2 (en) 1985-12-24 1991-03-14 Marion Laboratories, Inc. Use of synthetic sulfated saccharides to enhance wound healing
US4935349A (en) 1986-01-17 1990-06-19 Zymogenetics, Inc. Expression of higher eucaryotic genes in aspergillus
JP3179455B2 (ja) 1987-07-24 2001-06-25 カイロン コーポレイション エアーリフト昆虫細胞培養
US5024947A (en) 1987-07-24 1991-06-18 Cetus Corporation Serum free media for the growth on insect cells and expression of products thereby
DK463887D0 (da) 1987-09-07 1987-09-07 Novo Industri As Gaerleader
US5037743A (en) 1988-08-05 1991-08-06 Zymogenetics, Inc. BAR1 secretion signal
AU4647889A (en) 1988-11-18 1990-06-12 Cetus Corporation Insect signal peptide mediated secretion of recombinant proteins
GB8910962D0 (en) 1989-05-12 1989-06-28 Natural Environment Res Novel baculovirus expression vectors and use thereof in the expression of foreign proteins in insects or insect cells
US5162222A (en) 1989-07-07 1992-11-10 Guarino Linda A Use of baculovirus early promoters for expression of foreign genes in stably transformed insect cells or recombinant baculoviruses
US5077214A (en) 1989-07-07 1991-12-31 The Texas A&M University System Use of baculovirus early promoters for expression of foreign genes in stably transformed insect cells
US5023328A (en) 1989-08-04 1991-06-11 The Texas A&M University System Lepidopteran AKH signal sequence
US5155037A (en) 1989-08-04 1992-10-13 The Texas A&M University System Insect signal sequences useful to improve the efficiency of processing and secretion of foreign genes in insect systems
DK300090D0 (da) 1990-12-19 1990-12-19 Novo Nordisk As Fremgangsmaade til fremstilling af leadersekvenser
DK36392D0 (da) * 1992-03-19 1992-03-19 Novo Nordisk As Anvendelse af kemisk forbindelse
US5990077A (en) * 1995-04-14 1999-11-23 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
AU710818B2 (en) * 1996-03-01 1999-09-30 Novo Nordisk A/S Use of a pharmaceutical composition comprising an appetite-suppressing peptide

Also Published As

Publication number Publication date
DK0891378T3 (da) 2003-01-06
NO323043B1 (no) 2006-12-27
AU1871597A (en) 1997-09-16
NO2013006I1 (no) 2013-04-02
ES2187756T3 (es) 2003-06-16
EP1975177B1 (en) 2011-04-13
EP1231218B1 (en) 2008-05-14
AU710818B2 (en) 1999-09-30
ATE227737T1 (de) 2002-11-15
CY2013008I1 (el) 2015-08-05
EP1975177A1 (en) 2008-10-01
RU2197261C2 (ru) 2003-01-27
DE69717092T2 (de) 2003-07-24
CY2013008I2 (el) 2015-08-05
DE69740176D1 (de) 2011-05-26
KR19990087439A (ko) 1999-12-27
CZ297338B6 (cs) 2006-11-15
EP0891378B1 (en) 2002-11-13
HUP9902670A3 (en) 2000-02-28
DE69717092D1 (de) 2002-12-19
IL125805A0 (en) 1999-04-11
ES2364705T3 (es) 2011-09-12
CA2246733C (en) 2010-07-20
DK1975177T3 (da) 2011-07-25
KR100611130B1 (ko) 2006-11-30
JP4064460B2 (ja) 2008-03-19
DE69738695D1 (de) 2008-06-26
ES2306685T3 (es) 2008-11-16
CY2619B2 (pt) 2013-03-13
ATE395359T1 (de) 2008-05-15
PT1975177E (pt) 2011-07-26
CZ273698A3 (cs) 1998-12-16
EP1231218A3 (en) 2002-10-30
FR13C0009I1 (pt) 2013-03-22
HU229234B1 (en) 2013-09-30
WO1997031943A1 (en) 1997-09-04
NO2013006I2 (pt) 2013-03-12
ATE505485T1 (de) 2011-04-15
FR13C0009I2 (fr) 2013-08-16
EP2295453A2 (en) 2011-03-16
PL187095B1 (pl) 2004-05-31
NO984005D0 (no) 1998-08-31
EP1231218A2 (en) 2002-08-14
JP2000505460A (ja) 2000-05-09
NO984005L (no) 1998-08-31
PL328732A1 (en) 1999-02-15
CN1112367C (zh) 2003-06-25
UA70283C2 (en) 2004-10-15
CA2246733A1 (en) 1997-09-04
EP0891378A1 (en) 1999-01-20
CN1215405A (zh) 1999-04-28
EP2295453A3 (en) 2011-03-30

Similar Documents

Publication Publication Date Title
BR9707807A (pt) Uso de uma composição farmacêutica composição farmacêutica processo de tratar doenças ou distúrbios associados com a regulação do apetite prejudicado e uso de um peptideo
CA2321700A1 (en) Pharmaceutical composition for the treatment of functional dyspepsia and/or irritable bowel syndrome and new use of substances therein
DE69737916D1 (de) Verwendung von GLP-1 Peptiden
MXPA02006679A (es) Composicion farmaceutica.
IL208184A0 (en) Glp-1, and methods for treating diabetes
DE69719798D1 (de) Periphäre verabreichung von glp-1 analogen und derivate zur reguleirung der fettleibigkeit
BR9807673A (pt) Processos para tratar asma alérgica e dermatite em um humano e composição farmacêutica.
DK0470117T3 (da) Anvendelse af "calcitonin gene-related peptides" til fremstilling af lægemidler til behandling af erektile dysfunktioner
NO982935D0 (no) Hyaluronsyre reseptor bindende middel og anvendelse derav
BR0111852A (pt) Nova interferona para o tratamento de esclerose múltipla
KR950704358A (ko) 카텝신 l 특이적 저해 폴리펩티드
KR960003741A (ko) 조골세포 증식인자
RU2000117991A (ru) Способ лечения затяжных, рецидивирующих форм псевдотуберкулеза и его специфических осложнений у детей
MX9601655A (es) Proteinas (ob) obesas recombinantes.
BR0308322A (pt) Uso de uma variante de polipeptìdeo de interferon beta (ifnb), e, métodos para tratar ou prevenir derrame ou acidente cerebrovascular (avc) e ataque isquêmico em um primata

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: DE ACORDO COM O ART. 37, INDEFIRO O PRESENTE PEDIDO, UMA VEZ QUE NAO ATENDE AO REQUISITO DE ATIVIDADE INVENTIVA ( ART. 8O COMBINADO COM O ART. 13 DA LPI 9279/96).

B12B Appeal against refusal [chapter 12.2 patent gazette]